These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 35536530

  • 1. Recent progress in drug development for fibrodysplasia ossificans progressiva.
    Meng X, Wang H, Hao J.
    Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
    [Abstract] [Full Text] [Related]

  • 2. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN.
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [Abstract] [Full Text] [Related]

  • 3. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
    Wang H, Shore EM, Pignolo RJ, Kaplan FS.
    Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
    [Abstract] [Full Text] [Related]

  • 4. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC.
    Stem Cell Res Ther; 2016 Aug 17; 7(1):115. PubMed ID: 27530160
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M, Stoessel SJ, Yamamoto S, Goldhamer DJ.
    J Bone Miner Res; 2022 Nov 17; 37(11):2077-2093. PubMed ID: 35637634
    [Abstract] [Full Text] [Related]

  • 6. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
    Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S, Toguchida J.
    Proc Natl Acad Sci U S A; 2015 Dec 15; 112(50):15438-43. PubMed ID: 26621707
    [Abstract] [Full Text] [Related]

  • 7. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
    Luo Y, Alsamarah A, Zhang K, Hao J.
    Curr Mol Med; 2016 Dec 15; 16(1):4-11. PubMed ID: 26695699
    [Abstract] [Full Text] [Related]

  • 8. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
    Lin H, Shi F, Gao J, Hua P.
    Biosci Rep; 2019 Aug 30; 39(8):. PubMed ID: 31341010
    [Abstract] [Full Text] [Related]

  • 9. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW, Shore EM.
    Dev Dyn; 2022 Jan 30; 251(1):164-177. PubMed ID: 34133058
    [Abstract] [Full Text] [Related]

  • 10. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R, Cappato S, Bocciardi R.
    Bone; 2018 Apr 30; 109():187-191. PubMed ID: 29100956
    [Abstract] [Full Text] [Related]

  • 11. Granting immunity to FOP and catching heterotopic ossification in the Act.
    Kaplan FS, Pignolo RJ, Shore EM.
    Semin Cell Dev Biol; 2016 Jan 30; 49():30-6. PubMed ID: 26706149
    [Abstract] [Full Text] [Related]

  • 12. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
    Kaplan FS, Glaser DL, Pignolo RJ, Shore EM.
    Expert Opin Biol Ther; 2007 May 30; 7(5):705-12. PubMed ID: 17477807
    [Abstract] [Full Text] [Related]

  • 13. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL, Chakkalakal SA, Theosmy EG, Brennan TA, Kaplan FS, Shore EM.
    Stem Cells; 2014 May 30; 32(5):1289-300. PubMed ID: 24449086
    [Abstract] [Full Text] [Related]

  • 14. [Fibrodysplasia ossificans progressiva and osteoimmunology].
    Katagiri T.
    Clin Calcium; 2016 May 30; 26(5):691-8. PubMed ID: 27117614
    [Abstract] [Full Text] [Related]

  • 15. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
    Ye Z, Wang S, Shan C, Zhu Q, Xue Y, Zhang K.
    Orphanet J Rare Dis; 2023 May 10; 18(1):111. PubMed ID: 37165433
    [Abstract] [Full Text] [Related]

  • 16. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M, Kawao N, Okumoto K, Tamura Y, Okada K, Kaji H.
    J Biol Chem; 2014 Jun 13; 289(24):16966-77. PubMed ID: 24798338
    [Abstract] [Full Text] [Related]

  • 17. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva.
    Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, Shore EM.
    J Bone Miner Res; 2018 Feb 13; 33(2):269-282. PubMed ID: 28986986
    [Abstract] [Full Text] [Related]

  • 18. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
    Pang J, Zuo Y, Chen Y, Song L, Zhu Q, Yu J, Shan C, Cai Z, Hao J, Kaplan FS, Shore EM, Zhang K.
    Bone; 2016 Nov 13; 92():29-36. PubMed ID: 27492611
    [Abstract] [Full Text] [Related]

  • 19. Fibrodysplasia ossificans progressiva.
    Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM.
    Best Pract Res Clin Rheumatol; 2008 Mar 13; 22(1):191-205. PubMed ID: 18328989
    [Abstract] [Full Text] [Related]

  • 20. TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.
    de Ruiter RD, Wisse LE, Schoenmaker T, Yaqub M, Sánchez-Duffhues G, Eekhoff EMW, Micha D.
    Int J Mol Sci; 2023 Jan 24; 24(3):. PubMed ID: 36768622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.